Thienorphine: Receptor binding and behavioral effects in rhesus monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 1, 2007, Pages 227-236

  Li, Jun Xu ^a   Becker, Ginger L ^a   Traynor, John R ^b   Gong, Ze Hui ^c   France, Charles P ^a  

^a University of Texas Health Science Center   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; DELTA OPIATE RECEPTOR; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALTREXONE; NORBINALTORPHIMINE; ORIPAVINE; RADIOLIGAND; THIENORPHINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BEHAVIOR; BINDING AFFINITY; CELL FREE SYSTEM; CELL MEMBRANE; CHO CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; IN VITRO STUDY; IN VIVO STUDY; LATENT PERIOD; MACACA; MULTIPLE CYCLE TREATMENT; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; RHESUS MONKEY; SHOCK; THERMAL EXPOSURE;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ANALGESICS, NON-NARCOTIC; ANIMALS; BEHAVIOR, ANIMAL; BINDING, COMPETITIVE; BUPRENORPHINE; CELLS, CULTURED; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEAT; LIGANDS; MACACA MULATTA; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID; REINFORCEMENT SCHEDULE;

EID: 33947383615     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.113290     Document Type: Article

References (36)

1. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, and Johnson RE (1988) A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 43:72-78.
2. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
3. Brandt MR and France CP (1998) Chronic l-α acetylmethadol in rhesus monkeys: discriminative stimulus and other behavioral measures of dependence and withdrawal. J Pharmacol Exp Ther 287:1029-1037.
4. Butelman ER, Ko MC, Traynor JR, Vivian JA, Kreek MJ, and Woods JH (2001) GR89,696: a potent κ-opioid agonist with subtype selectivity in rhesus monkeys. J Pharmacol Exp Ther 298:1049-1059.
5. Butelman ER, Negus SS, Ai Y, de Costa BR, and Woods JH (1993) Kappa opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys. J Pharmacol Exp Ther 267:1269-1276.
6. Chawarski MC, Moody DE, Pakes J, O'Connor PG, and Schottenfeld RS (2005) Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms. J Subst Abuse Treat 29:307-312.
7. Cheng Y-C and Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
8. Colpaert FC (1999) Drug discrimination in neurobiology. Pharmacol Biochem Behav 64:337-345.
9. Cowan A, Lewis JW, and Macfarlane IR (1977) Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 60:537-545.
10. Dykstra LA, Gmerek DE, Winger G, and Woods JH (1987) κ Opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. J Pharmacol Exp Ther 242:413-420.
11. Dykstra LA and Woods JH (1986) A tail withdrawal procedure for assessing analgesic activity in rhesus monkeys. J Pharmacol Methods 15:263-269.
12. Emmerson PJ, Liu MR, Woods JH, and Medzihradsky F (1994) Binding affinity and selectivity of opioids at μ, δ, and κ receptors in monkey brain membranes. J Pharmacol Exp Ther 271:1630-1637.
13. France CP and Woods JH (1989) Discriminative stimulus effects of naltrexone in morphine-treated rhesus monkeys. J Pharmacol Exp Ther 250:937-943.
14. Gellert VF and Holtzman SG (1979) Discriminative stimulus effects of naltrexone in the morphine-dependent rat. J Pharmacol Exp Ther 211:596-605.
15. Gerak LR, Gauthier CA, and France CP (2003) Discriminative stimulus and antinociceptive effects of dihydroetorphine in rhesus monkeys. Psychopharmacology (Berl) 166:351-359.
16. Heel RC, Brogden RN, Speight TM, and Avery GS (1979) Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs 17:81-110.
17. Katz JL (1986) Effects of clonidine and morphine on opioid withdrawal in rhesus monkeys. Pscyhopharmacology 88:392-397.
18. 2 analysis in rhesus monkeys. J Pharmacol Exp Ther 285:518-526.
19. Kosten TR and Kleber HD (1988) Buprenorphine detoxification from opioid dependence: a pilot study. Life Sci 42:635-641.
20. Kumor KM, Haertzen CA, Johnson RE, Kocher T, and Jasinski D (1986) Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. J Pharmacol Exp Ther 238:960-968.
21. Leander JD (1987) Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology 26:1445-1447.
22. Lee KO, Akil H, Woods JH, and Traynor JR (1999) Differential binding properties of oripavines at cloned mu- and delta-opioid receptors. Eur J Pharmacol 378:323-330.
23. Lelas S, Wegert S, Otton SV, Sellers EM, and France CP (1999) Inhibitors of cytochrome P450. Differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys. Drug Alcohol Depend 54:239-249.
24. Liu H, Zhong BH, Liu CH, Wu B, and Gong ZH (2005) Synthesis, crystal structure and pharmacological study of N-cyclopropylmethyl-7α-[1- (R)-1-hydroxy-1-methyl-3-(thien-2-yl) propyl]-6,14-endo-ethanotetrahydro- oripavine. Acta Chim Slov 52:80-85.
25. McMahon LR, Sell SL, and France CP (2004) Cocaine and other indirect-acting monoamine agonists differentially attenuate a naltrexone discriminative stimulus in morphine-treated rhesus monkeys. J Pharmacol Exp Ther 308:111-119.
26. Mello NK and Negus SS (2000) Interactions between kappa opioid agonists and cocaine. Preclinical studies. Ann NY Acad Sci 909:104-132.
27. Pick CG, Peter Y, Schreiber S, and Weizman R (1997) Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with kappa 3 analgesia. Brain Res 744:41-46.
28. Porsolt RD, Lemaire M, Durmuller N, and Roux S (2002) New perspectives in CNS safety pharmacology. Fundam Clin Pharmacol 16:197-207.
29. San L, Torrens M, Castillo C, Porta M, de la Torre R (1993) Consumption of buprenorphine and other drugs among heroin addicts under ambulatory treatment: results from cross-sectional studies in 1988 and 1990. Addiction 88:1341-1349.
30. Sell SL, McMahon LR, and France CP (2003) Relative efficacy of buprenorphine, nalbuphine and morphine in opioid-treated rhesus monkeys discriminating naltrexone. J Pharmacol Exp Ther 306:1167-1173.
31. Sell SL, McMahon LR, Koek W, and France CP (2005) Monoaminergic drugs and directly observable signs of LAAM withdrawal in rhesus monkeys. Behav Pharmacol 16:53-58.
32. Traynor JR, Clark MJ, and Remmers AE (2002) Relationship between rate and extent of G protein activation: comparison between full and partial opioid agonists. J Pharmacol Exp Ther 300:157-161.
33. Traynor JR and Woods JH (2005) Drug evaluation committee report on evaluation of new compounds for opioid activity (2005). National Institute on Drug Abuse Research Monograph 186 (Dewey WL ed) pp 163-186, National Institute on Drug Abuse, Bethesda, MD.
34. Yu G, Yue YJ, Cui MX, and Gong ZH (2006) Thienorphine is a potent long-acting partial opioid agonist: a comparative study with buprenorphine. J Pharmacol Exp Ther 318:282-287.
35. Zhao WL, Gong ZH, and Liang JH (2004) A new buprenorphine analogy, thenorphine, inhibits morphine-induced behavioral sensitization in mice. Acta Pharmacol Sin 25:1413-1418.
36. 35S] GTPγS binding to membranes: determination of potencies and efficacies of ligands. J Pharmacol Exp Ther 282:676-684.